Cellcept can be taken with or without food, but consistency is important. Take at the same time each day. Do not crush, chew, or open capsules/tablets. Administer IV infusion slowly over no less than 2 hours.

Mycophenolate mofetil is rapidly converted to mycophenolic acid (MPA), which is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This inhibition blocks the de novo pathway of guanosine nucleotide synthesis, to which lymphocytes are critically dependent for proliferation, thereby exhibiting cytostatic effects on lymphocytes.

• •Hypersensitivity to mycophenolate mofetil, mycophenolic acid, or any component of the formulation.
• •Pregnancy (unless no suitable alternative due to significant risk of birth defects).
• •Lactation.

Store at room temperature (20-25°C or 68-77°F). Protect from moisture and light. Keep bottles tightly closed. Oral suspension should be refrigerated after reconstitution and discarded after recommended period. Keep out of reach of children.

Overdose can lead to severe myelosuppression (leukopenia, neutropenia), gastrointestinal disturbances, and increased risk of infection. Management is supportive; hemodialysis can remove the inactive metabolite MPAG but not MPA effectively. Cholestyramine may reduce MPA levels by interrupting enterohepatic recirculation.

Pregnancy Category D. Contraindicated due to high risk of birth defects (e.g., ear, heart, facial anomalies) and miscarriage. Use highly effective contraception during treatment and for 6 weeks after stopping. Avoid during lactation as MPA is excreted in breast milk and may harm the infant.